A bispecific antibody targeting the T-cell co-receptor CD3ε and the immune checkpoint programmed-death ligand 1 on dendritic cells rejuvenates tumour-specific CD8 T cells, leading to durable antitumour responses in murine models of cancer.
Nature Reviews Clinical Oncology – ALND can be safely omitted for patients with sentinel-node macrometastases
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
Nature Reviews Clinical Oncology – T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers…
Nature Reviews Clinical Oncology – The benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer…
Nature Reviews Clinical Oncology – Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
Nature Reviews Clinical Oncology – Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα…
FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
Nature Reviews Clinical Oncology – A new standard of care for advanced-stage urothelial carcinoma
